ATE449789T1 - Pacap-peptidanaloga - Google Patents

Pacap-peptidanaloga

Info

Publication number
ATE449789T1
ATE449789T1 AT99920844T AT99920844T ATE449789T1 AT E449789 T1 ATE449789 T1 AT E449789T1 AT 99920844 T AT99920844 T AT 99920844T AT 99920844 T AT99920844 T AT 99920844T AT E449789 T1 ATE449789 T1 AT E449789T1
Authority
AT
Austria
Prior art keywords
peptide analogue
pacap peptide
pacap
analogue
peptide
Prior art date
Application number
AT99920844T
Other languages
English (en)
Inventor
Zheng Dong
Original Assignee
Ipsen Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma filed Critical Ipsen Pharma
Application granted granted Critical
Publication of ATE449789T1 publication Critical patent/ATE449789T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
AT99920844T 1998-07-20 1999-04-30 Pacap-peptidanaloga ATE449789T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11954098A 1998-07-20 1998-07-20
PCT/EP1999/003020 WO2000005260A1 (en) 1998-07-20 1999-04-30 Peptide analogues of pacap

Publications (1)

Publication Number Publication Date
ATE449789T1 true ATE449789T1 (de) 2009-12-15

Family

ID=22384966

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99920844T ATE449789T1 (de) 1998-07-20 1999-04-30 Pacap-peptidanaloga

Country Status (15)

Country Link
EP (2) EP1098906B1 (de)
JP (2) JP2002521390A (de)
AR (1) AR019131A1 (de)
AT (1) ATE449789T1 (de)
AU (1) AU3826899A (de)
CA (1) CA2335341A1 (de)
CZ (1) CZ2001253A3 (de)
DE (1) DE69941708D1 (de)
DK (1) DK1098906T3 (de)
ES (1) ES2335827T3 (de)
HU (1) HUP0104934A3 (de)
NO (1) NO20010284L (de)
PL (1) PL345583A1 (de)
TW (1) TWI221845B (de)
WO (1) WO2000005260A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972319B1 (en) 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
CA2379604A1 (en) * 1999-09-28 2001-04-05 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
EP1233811A2 (de) 1999-11-12 2002-08-28 Leo Rubin Verfahren zur behandlung von herzstillstand oder pulmonarer hypertension und substanzen zur verwendung dafür mit vasoaktivem intestinalen polypeptid und kardiales gerät zur elektrischen und chemischen regulation sowie verwendungsverfahren dafür
US6489297B1 (en) 2000-02-18 2002-12-03 Dabur Research Foundation Vasoactive intestinal peptide analogs
WO2001060863A1 (en) * 2000-02-18 2001-08-23 Dabur Research Foundation Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
AU2072002A (en) * 2000-11-28 2002-06-11 Mondobiotech Sa Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
JP2002293799A (ja) * 2001-03-29 2002-10-09 Itoham Foods Inc 新規ペプチド及びそれを含有する消化管運動抑制剤
AR036400A1 (es) * 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
ATE541921T1 (de) * 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
AU2003228050A1 (en) * 2002-05-03 2003-11-17 Neuronova Ab Therapeutic use of PACAP, Maxadilan, PACAP receptor agonist and/or ADCYAP1R1 in the treatment of CNS disorders
AU2003236072B2 (en) * 2002-06-10 2008-10-23 Mondobiotech Ag Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
CA2492442A1 (en) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
WO2004062684A2 (en) 2003-01-16 2004-07-29 D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven Treatment of thrombocytopenia with inhibitors of pacap
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US7595294B2 (en) * 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
JP2006306770A (ja) * 2005-04-27 2006-11-09 Nidek Co Ltd 眼疾患治療剤
WO2007036033A1 (en) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
CN101296708B (zh) 2005-10-26 2011-12-07 伊莱利利公司 选择性vpac2受体肽激动剂
CA2779496A1 (en) * 2009-11-02 2011-05-05 The Administrators Of The Tulane Educational Fund Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CA2901231C (en) * 2013-02-15 2020-06-23 Thomas Jefferson University Kit comprising lyophilized compositions for tumor imaging
CA2906737C (en) 2013-03-15 2023-08-15 Amgen Inc. Human pac1 antibodies
US20160122406A1 (en) * 2013-06-07 2016-05-05 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
WO2015023890A1 (en) 2013-08-14 2015-02-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
WO2015100353A1 (en) 2013-12-27 2015-07-02 Dignity Health Diagnosing and treating alzheimer's disease
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
EP3565573B1 (de) 2017-01-05 2023-08-23 The Regents of The University of California Pac1-rezeptor-agonisten (maxcaps) und verwendungen davon
SG11202006610YA (en) 2018-01-12 2020-08-28 Amgen Inc Pac1 antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS277405B6 (en) * 1986-06-12 1993-03-17 Vyzk Ustav Farm Biochem Sp Peptides with 1-amino-1-cycloalkane carboxylic acid
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5623050A (en) * 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
JP3354173B2 (ja) * 1991-08-22 2002-12-09 武田薬品工業株式会社 ポリペプチドおよびその用途
JPH10505863A (ja) * 1994-09-22 1998-06-09 ジ・アドミニストレーターズ・オブ・ザ・チューレン・エデュケイショナル・ファンド 脳障害の予防および治療のための方法および医薬組成物
EP0820296A4 (de) * 1995-04-14 1999-06-30 Univ Tulane Analoge von wachstumshormon-freisetzungsfaktor
US5753206A (en) * 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
EP0796867B1 (de) * 1995-06-09 2003-11-05 Itoham Foods Inc. Peptide, bronchodilator und den blutstrom verbesserndes mittel
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
AU6846196A (en) * 1995-08-15 1997-03-12 International Software Machines Programmable compiler

Also Published As

Publication number Publication date
EP1098906B1 (de) 2009-11-25
EP2161282A1 (de) 2010-03-10
JP2002521390A (ja) 2002-07-16
NO20010284D0 (no) 2001-01-17
AU3826899A (en) 2000-02-14
HUP0104934A2 (hu) 2002-04-29
EP1098906A1 (de) 2001-05-16
HUP0104934A3 (en) 2002-05-28
AR019131A1 (es) 2001-12-26
JP2010189398A (ja) 2010-09-02
ES2335827T3 (es) 2010-04-05
CA2335341A1 (en) 2000-02-03
CZ2001253A3 (cs) 2001-11-14
NO20010284L (no) 2001-03-19
WO2000005260A1 (en) 2000-02-03
TWI221845B (en) 2004-10-11
DK1098906T3 (da) 2010-03-29
DE69941708D1 (de) 2010-01-07
PL345583A1 (en) 2001-12-17

Similar Documents

Publication Publication Date Title
ATE449789T1 (de) Pacap-peptidanaloga
NO982097D0 (no) Peptider
NO982098D0 (no) Peptider
EE200100080A (et) C-hepatiidi inhibiitorpeptiidid
DE69920011D1 (de) Rekombinanter venezolanische-equine-pferdeenzephalitis-virusimpstoff
ATE228357T1 (de) Nukleotid-analoge zusammensetzung
ATE288410T1 (de) Vitamin d-analoga
DE59902471D1 (de) Kommissionieranlage
ATE321784T1 (de) Pthrp analogen
DK1070058T3 (da) (4-Arylsulfonylamino)-tetrahydropyran-4-carboxylsyrehydroxamider
DE59910376D1 (de) Schleuderstreuer
NO985680D0 (no) Peptidderivater
DE69902762D1 (de) Riser-spannanordnung
FR2787514B1 (fr) Propulseur
NO983849D0 (no) Peptidderivater
NO20002555D0 (no) Skjøt
DE19982534D2 (de) Spriegelausführung
ID30477A (id) Analog nukleosida antivirus
FR2782671B3 (fr) Livre
DE69925271D1 (de) Angiostatin-bindendes protein
DK0862850T3 (da) Mejetærsker
EP1159288A4 (de) Alpha-conotoxin-peptide
NO20012283D0 (no) Koblede peptider
KR980000237U (ko) 넥타이
NO995788D0 (no) Arbeidsbord

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties